---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-093550"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2021-07-19T23:59:59+00:00"
generated_at: "2026-06-30T04:36:52.240293+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition Corp. prices $40M IPO; 4M units at $10 each

## Summary
- IPO of 4,000,000 units at $10.00/unit, gross proceeds of $40 million; over-allotment option of 600,000 units available.
- Private placement of 295,000 shares to founders at $10/share, raising $2.95 million concurrent with IPO closing.
- Net proceeds of $40.8 million ($40M IPO + $0.8M private placement) placed in trust account for business combination.
- Board classified: Weston Twigg (Class I, 2022), Tao Jiang & James Long (Class II, 2023), Jianwei Li & Weiguang Yang (Class III, 2024).
- Units listed on Nasdaq under UPTDU starting July 15; common stock (UPTD) and warrants (UPTDW) will trade separately later.

## SEC filing metadata
- accession: 0001104659-21-093550
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2021-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/tm2122516d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-093550
- JSON: https://secwatch.observer/filing/0001104659-21-093550.json
- Plain text: https://secwatch.observer/filing/0001104659-21-093550.txt

## Key facts
- Executive change
  James Long was appointed as Director at Estrella Immunopharma, Inc..
  - Action: became director
  - Role: Director
  source text: Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm
- Executive change
  Weston Twigg was appointed as Director at Estrella Immunopharma, Inc..
  - Action: became director
  - Role: Director
  source text: Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm
- Executive change
  Tao Jiang was appointed as Director at Estrella Immunopharma, Inc..
  - Action: became director
  - Role: Director
  source text: Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000110465921093550/0001104659-21-093550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.